BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• BeOne Medicines Ltd. has received an average rating of "Moderate Buy" from ten brokerage firms, with a target price of $340.30.
• Insider transactions included COO Xiaobin Wu selling 49,858 shares at an average price of $304.16, totaling over $15 million.
• The stock has seen a 1.5% decline, and currently trades around $316.15, with a market capitalization of approximately $34.65 billion.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has earned an average rating of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $340.30.

A number of analysts recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Zacks Research upgraded shares of BeOne Medicines from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 18th. Guggenheim increased their price target on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Friday, October 3rd. Finally, Barclays initiated coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They issued an "overweight" rating and a $385.00 price target on the stock.

Insider Buying and Selling

In other news, COO Xiaobin Wu sold 49,858 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $304.16, for a total value of $15,164,809.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lai Wang sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total value of $1,750,300.00. The disclosure for this sale can be found here. Insiders sold a total of 164,184 shares of company stock valued at $51,534,146 over the last three months. 6.62% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BeOne Medicines

Several large investors have recently modified their holdings of ONC. Anchor Investment Management LLC acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $28,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $35,000. Farther Finance Advisors LLC acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $39,000. Finally, Signaturefd LLC acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $49,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Stock Down 1.5%

ONC stock opened at $316.15 on Thursday. The company's 50 day moving average price is $323.50 and its 200 day moving average price is $277.84. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.72 and a current ratio of 1.95. BeOne Medicines has a fifty-two week low of $170.99 and a fifty-two week high of $355.30. The firm has a market capitalization of $34.65 billion, a price-to-earnings ratio of -182.74 and a beta of 0.31.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.24 billion. On average, equities research analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.